Dual GLP-1/Glucagon Agonists (Survodutide): A Bridge Between Obesity and Liver Disease
Introduction For decades, obesity and liver disease have been treated as separate epidemics. One has been measured by the scale, the other by liver enzymes and biopsies. Yet biology tells a different story: metabolic dysfunction lies at the heart of both. Now, a new class of therapies seeks to unite these worlds. Survodutide, developed by […]
